PubMed (MeSH Keyword) for id: 71183216

Year	Number of Results
2016	4
2017	4
2018	1
2019	1
2020	1
2024	0

1

GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Potet F, Egecioglu DE, Burridge PW, George AL Jr. Potet F, et al. Mol Pharmacol. 2020 Nov;98(5):540-547. doi: 10.1124/molpharm.120.000048. Epub 2020 Sep 16. Mol Pharmacol. 2020. PMID: 32938719

2

Increase in CO₂ levels by upregulating late sodium current is proarrhythmic in the heart.

Zhang Q, Ma JH, Li H, Wei XH, Zheng J, Li G, Wang CY, Wu Y, He QH, Wu L. Zhang Q, et al. Heart Rhythm. 2019 Jul;16(7):1098-1106. doi: 10.1016/j.hrthm.2019.01.029. Epub 2019 Jan 31. Heart Rhythm. 2019. PMID: 30710739

3

Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na⁺ current.

El-Bizri N, Xie C, Liu L, Limberis J, Krause M, Hirakawa R, Nguyen S, Tabuena DR, Belardinelli L, Kahlig KM. El-Bizri N, et al. Heart Rhythm. 2018 Feb;15(2):277-286. doi: 10.1016/j.hrthm.2017.09.028. Epub 2017 Oct 7. Heart Rhythm. 2018. PMID: 29017927

4

Inhibition of late sodium current suppresses calcium-related ventricular arrhythmias by reducing the phosphorylation of CaMK-II and sodium channel expressions.

Wei XH, Yu SD, Ren L, Huang SH, Yang QM, Wang P, Chu YP, Yang W, Ding YS, Huo Y, Wu L. Wei XH, et al. Sci Rep. 2017 Apr 20;7(1):981. doi: 10.1038/s41598-017-01056-0. Sci Rep. 2017. PMID: 28428622 Free PMC article.

5

The Selective Late Sodium Current Inhibitor Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation.

Silva AF, Bonatti R, Batatinha JA, Nearing BD, Zeng D, Belardinelli L, Verrier RL. Silva AF, et al. J Cardiovasc Pharmacol. 2017 Mar;69(3):178-182. doi: 10.1097/FJC.0000000000000455. J Cardiovasc Pharmacol. 2017. PMID: 28045761

6

Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model.

Bacic D, Carneiro JS, Bento AA, Nearing BD, Rajamani S, Belardinelli L, Verrier RL. Bacic D, et al. Heart Rhythm. 2017 Mar;14(3):448-454. doi: 10.1016/j.hrthm.2016.10.021. Epub 2016 Oct 21. Heart Rhythm. 2017. PMID: 27777148

7

The novel late Na⁺ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations.

Rajamani S, Liu G, El-Bizri N, Guo D, Li C, Chen XL, Kahlig KM, Mollova N, Elzein E, Zablocki J, Belardinelli L. Rajamani S, et al. Br J Pharmacol. 2016 Nov;173(21):3088-3098. doi: 10.1111/bph.13563. Epub 2016 Sep 14. Br J Pharmacol. 2016. PMID: 27449698 Free PMC article.

8

Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation.

Justo F, Fuller H, Nearing BD, Rajamani S, Belardinelli L, Verrier RL. Justo F, et al. Heart Rhythm. 2016 Sep;13(9):1860-7. doi: 10.1016/j.hrthm.2016.06.020. Epub 2016 Jun 16. Heart Rhythm. 2016. PMID: 27317981

9

Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model.

Fuller H, Justo F, Nearing BD, Kahlig KM, Rajamani S, Belardinelli L, Verrier RL. Fuller H, et al. Heart Rhythm. 2016 Aug;13(8):1679-86. doi: 10.1016/j.hrthm.2016.04.015. Epub 2016 Apr 21. Heart Rhythm. 2016. PMID: 27108587

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9 results

Results by year